Psoriasis exacerbation following intravesical BCG immunotherapy for bladder carcinoma: A case report

To Editor,Psoriasis is a chronic, immune-mediated inflammatory disease with a broad spectrum of clinical manifestations that can be out or exacerbated by genetic and environmental factors 1 .Exacerbations of psoriasis have been observed after administering influenza, tetanus-diphtheria, and Bacillus Calmette-Guérin (BCG) vaccines 2-4 .Additionally, BCG immunotherapy, used to treat bladder cancer, may be one of the causes of psoriasis flare-ups 5 .Here, we present a male patient with psoriasis vulgaris who had psoriasis exacerbation following intravesical BCG immunotherapy for bladder carcinoma treatment.A 58-year-old male with a history of psoriasis vulgaris applied to our dermatology outpatient clinic due to a flare-up of his lesions.He was diagnosed with psoriasis 23 years ago and used topical treatments, methotrexate, cyclosporine, infliximab, and adalimumab for the disease in the past.Over the past two years, his psoriasis had been completely clear under ustekinumab.After he was diagnosed with invasive urothelial carcinoma, ustekinumab was stopped.Three months after taking intravesical BCG immunotherapy, one week after the third dose, pruritic lesions occurred on his body.He had no recent history of infection or allergy.